Gyre Therapeutics, Inc. (NASDAQ: GYRE) is a Healthcare company (Biotechnology) with a market capitalization of $499M. The Maz Rating grades it against the other companies in its sector.
Gyre Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $4.56, Gyre Therapeutics, Inc. trades at 4.1x sales and 4.5x book value. Over the last twelve months it generated about $122M of revenue and a net loss of $31M. It runs a gross margin of 94.1%, an operating margin of -20.6% and a net margin of -20.5%. It shows return on equity of -22.4%, return on invested capital of -14.5% and a free cash flow yield of -5.2%. On the balance sheet: a debt-to-equity ratio of 0.03 and a current ratio of 4.32. Over the past 52 weeks the share price ranged from $3.97 to $9.14, with a beta of 4.74.
Gyre Therapeutics, Inc. does not currently pay a dividend.
1 Wall Street analyst rating covers the stock: 1 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.